Showing results (81-90 of 159) with videos related to
Sort By:
Pageof 16
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 2, 2021
Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)Andrew Blauvelt, Craig L Leonardi, Norman Gaylis, et al.Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyAlice B Gottlieb, Robert T Matheson, Alan Menter, et al.Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.Archives of Dermatology|June 20, 2007
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasisStephen Tyring, Kenneth B Gordon, Yves Poulin, et al.The Journal of Dermatological Treatment|March 17, 2007
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activityAmir A Toor, Patrick J Stiff, Brian J Nickoloff, et al.Journal of the American Academy of Dermatology|November 23, 2006
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasisAngela Moore, Kenneth B Gordon, Sewon Kang, et al.Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.Journal of the American Academy of Dermatology|May 19, 2015
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)Ulrich Mrowietz, Craig L Leonardi, Giampiero Girolomoni, et al.Journal of Drugs in Dermatology : JDD|August 16, 2021
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)Kim A Papp, Sascha Gerdes, Craig L Leonardi, et al.Journal of the American Academy of Dermatology|February 21, 2006
Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy databaseAlice B Gottlieb, Craig L Leonardi, Bernard S Goffe, et al.Pageof 16